Cargando…

Deferred autologous stem cell transplantation in systemic AL amyloidosis

High-dose melphalan with autologous stem cell transplantation (ASCT) can induce durable haematological and organ responses in systemic AL amyloidosis (AL). Stringent selection criteria have improved safety of ASCT in AL but most patients are transplant-ineligible. We report our experience of deferre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manwani, Richa, Hegenbart, Ute, Mahmood, Shameem, Sachchithanantham, Sajitha, Kyriakou, Charalampia, Yong, Kwee, Popat, Rakesh, Rabin, Neil, Whelan, Carol, Dittrich, Tobias, Kimmich, Christoph, Hawkins, Philip, Schönland, Stefan, Wechalekar, Ashutosh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218452/ https://www.ncbi.nlm.nih.gov/pubmed/30397193 http://dx.doi.org/10.1038/s41408-018-0137-9

Ejemplares similares

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
por: Sharpley, Faye A., et al.
Publicado: (2019)

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
por: Sharpley, Faye A., et al.
Publicado: (2020)

(99m)Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
por: Quarta, Candida Cristina, et al.
Publicado: (2021)

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
por: Ravichandran, Sriram, et al.
Publicado: (2021)

MR-Neurography of the sural nerve in patients with hereditary amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2015)

The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis
por: Cohen, Oliver C., et al.
Publicado: (2020)

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis
por: Quarta, Candida Cristina, et al.
Publicado: (2017)

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
por: Lecat, Catherine S. Y., et al.
Publicado: (2021)

Updates in Cardiac Amyloidosis: A Review
por: Banypersad, Sanjay M., et al.
Publicado: (2012)

PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
por: Sridhar, Amrutha, et al.
Publicado: (2023)

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
por: Martinez-Naharro, Ana, et al.
Publicado: (2022)

OR14-001 – Tocilizumab in autoinflammation and AA amyloidosis
por: Lane, T, et al.
Publicado: (2013)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
por: Asher, Samir, et al.
Publicado: (2022)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
por: Wagner, T., et al.
Publicado: (2018)

The Evolving Epidemiology of Amyloidosis
por: Wechalekar, Ashutosh D.
Publicado: (2021)

Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
por: Ravichandran, Sriram, et al.
Publicado: (2022)

DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience
por: Hutt, David, et al.
Publicado: (2015)

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
por: Wong, Sandy W., et al.
Publicado: (2018)

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
por: Berghaus, Natalie, et al.
Publicado: (2022)

P910: DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS
por: Khwaja, Jahanzaib, et al.
Publicado: (2023)

OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines
por: Chan, Wei Yee, et al.
Publicado: (2021)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: Minnema, Monique, et al.
Publicado: (2023)

Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2021)

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study
por: Camilleri, Marquita, et al.
Publicado: (2022)

Extensive cardiac FDG uptake in a patient with AL amyloidosis
por: Hatipoglu, Suzan, et al.
Publicado: (2023)

Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
por: Lisenko, Katharina, et al.
Publicado: (2016)

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
por: Chan, Wei Yee, et al.
Publicado: (2021)

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
por: Hegenbart, Ute, et al.
Publicado: (2017)

Diagnostic value of fat aspirates for amyloidosis in 950 patients
por: Gilbertson, JA, et al.
Publicado: (2015)

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
por: Havasi, Andrea, et al.
Publicado: (2022)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jfli065vdf88vi7oiut8uc03gl